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The Institute for Immunology and Informatics (iCubed) at the University of Rhode Island
held its 8th Annual Vaccine Renaissance on October 13-16, 2014. The conference serves
as an annual nexus for conversations related to vaccine design, discovery, and vaccine
acceptance. The annual event strives to provide a unique, interactive forum for the
discussion of cutting-edge vaccine research, including the design and use of new tools
and techniques for accelerating vaccine discovery. The conference also provides
academic researchers, vaccine industry leaders and students of vaccinology with an
opportunity to foster new professional relationships. Furthermore, the organizers of the
8th Annual Vaccine Renaissance are committed to extending attendance and presentation
opportunities to young scientists and „scientific minorities,‟ such as women, students
from historically black colleges and universities (HBCUs), and individuals not native to
the United States. The conference organizing committee invites such participants to
present their research as a poster, and has organized “meet-the-expert” roundtable
discussions as a way of conferring with experts.
Participants contributed to reports about developing vaccines against emerging infectious
diseases and research updates on the effect of the human microbiome in responses to

vaccines. Field experts also described new cancer vaccine designs, provided overviews
on the current state of animal vaccine research, and reported on HPV vaccine acceptance
by at-risk populations. The four-day symposium included a one-day pre-conference, in
which participants discussed their research involving the JanusMatrix tool developed by
De Groot and colleagues [1]. The last day of the event provided opportunities for
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attendees gain hands-on experience in a variety of laboratory techniques as well as
training on the iVAX suite of bioinformatics tools.
Nearly 100 individuals from industry, academia, and federal agencies such as the Walter
Reed Army Institute of Research (WRAIR), the United States Army Medical Research
Institute of Infectious Diseases (USAMRIID), the Department of Agriculture (USDA),
and the National Institutes of Health (NIH) attended the conference. In addition to
luminaries such as Bruno Guy (Sanofi Pasteur), Polly Matzinger (Laboratory of
Immunogenetics, National Institute of Allergy and Infectious Disease), Thomas Nutman
(Laboratory of Parasitic Diseases,

NIH), Amy Rosenberg (Food and Drug

Administration), Edward T. Ryan (Massachusetts General Hospital, Harvard Chan
School of Public Health). Papers were presented by John Julias (United States
Department of Homeland Security), Kimberly A. Kraynyak (Inovio Pharmaceuticals),
Steve Meshnick (Department of Epidemiology, UNC Gillings School of Global Public
Health) and Peter B. McGarvey (Innovation Center for Biomedical Informatics,
Georgetown University Medical Center). Presenters represented a variety of affiliations
as well as health-related interests, which stimulated participants to draw inferences and
conceive connections between their colleagues‟ novel ideas and their individual research
programs.

After the conference, presenters are invited to submit a manuscript related to their
presentation, to the peer-review journal Human Vaccines & Immunotherapeutics
(HV&I). Five speakers have accepted the invitation to submit, and their articles can be
found within the current issue of HV&I. In this 8th compendium of papers, we are pleased
to offer a selection of reports that focus on the means to rapidly develop safer, more
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effective vaccines. In sequential order of authors and their topics is as follows: Moise et
al. [2] describes the iVAX suite of tools along with their applications for the design of
vaccines for Tularemia, Smallpox, H. Pylori, Burkholderia, HCV, Lassa virus or H1N1
and H7N9. Eickhoff et al. describe the immunoinformatic strategy and in vivo validation
of the identification of 30 epitopes that could be used in the design of Chagas disease
vaccine [3]. Rose et al. discuss the choice of the adjuvant during vaccine design and
demonstrate that while the adjuvants do increase the innate response in mice injected
with piggyBac plasmids, no adjuvant increases the level of transfection of the antigen [4].
Carjaval-Yepes et al. developed a cellular model of IFNAR1-knocked-down avian cells
that can produce H1N1 viruses and HA protein, and propose an alternative method of
production of Influenza vaccines [5]. Lastly, Jamieson discusses the genetic and
environmental factors that influence response to vaccination, with a special emphasis on
the microbiome [6].
Two additional papers not included in this compendium have been accepted for
publication and will be published out soon after the printing of this compendium. In those
two manuscripts, Hoffmann et al. present their pre-clinical work on the development of a
cancer vaccine targeting survivin expressing tumor cells. HIvax peptides expressed in
Fowlpox vectors activate antigen-specific CD4+ and CD8+ T cells in healthy donors,

providing a rationale to move on to the clinical stage of the vaccine development [7]. Liu
et al. present an immunoinformatics analysis of H7N9 T cell epitopes, providing a
possible explanation for immune resistance to inactivated H7 HA vaccines. The results
demonstrate that HA epitopes containing TCR facing residues identical to self-proteins
can activate FoxP3+ Tregs, thus inducing immune tolerance and H7N9 “camouflage”

Downloaded by [University Of Rhode Island], [Austin Menge] at 13:10 16 July 2015

from the immune response [8].
The variety of topics and expertise contained within the following reports is an accurate
representation of the Vaccine Renaissance and its attendees. Qualitative exit surveys
suggest that participants appreciate the interactive and interdisciplinary nature of the
Vaccine Renaissance. The 9th Annual Vaccine Renaissance is scheduled to be held
November 4-6, 215 in Providence, Rhode Island, with informatics training held on
Friday, November 6th. Please visit www.immunome.org for a list of speakers and to view
the schedule of events.
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